Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1830896 | 1.00 | HTR4 (0.44) | HTR4SIGMAR1PIK3CDDRD3CYP1A2 | |
| SCHEMBL1831926 | 1.00 | HTR4 (0.44) | HTR4SIGMAR1PIK3CDDRD3CYP1A2 | |
| SCHEMBL4781372 | 0.82 | DRD3 (0.43) | HTR4SIGMAR1PIK3CDDRD3CYP1A2 | |
| SCHEMBL4781369 | 0.82 | DRD3 (0.43) | HTR4SIGMAR1PIK3CDDRD3CYP1A2 | |
| SCHEMBL1830029 | 0.82 | DRD3 (0.43) | HTR4SIGMAR1PIK3CDDRD3CYP1A2 | |
| SCHEMBL4106088 | 0.80 | HTR4 (0.43) | HTR4SIGMAR1PIK3CDDRD3CYP1A2 | |
| SCHEMBL5193602 | 0.80 | HTR4 (0.43) | HTR4SIGMAR1PIK3CDDRD3CYP1A2 | |
| SCHEMBL6021882 | 0.80 | HTR4 (0.43) | HTR4SIGMAR1PIK3CDDRD3CYP1A2 | |
| SCHEMBL23113778 | 0.76 | DRD3 (0.36) | HTR4SIGMAR1PIK3CDDRD3CYP1A2 | |
| SCHEMBL23823660 | 0.76 | CYP1A2 (0.64) | SIGMAR1PIK3CDDRD3CYP1A2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4463457-B1 | PYRROLO[1,2-B]-2-PYRIDAZINONE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LTD (IN) | 2026-02-04 | — | — | EP | disclosed |
| US-12275746-B2 | Pyrrolo[1,2-b]-2-pyridazinone compounds as 5-HT4 receptor agonists | SUVEN LIFE SCIENCES LIMITED (IN) | 2025-04-15 | — | — | US | disclosed |
| US-20250019386-A1 | PYRROLO[1,2-b]-2-PYRIDAZINONE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2025-01-16 | — | — | US | disclosed |
| EP-4463457-A1 | PYRROLO[1,2-/b]-2-PYRIDAZINONE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | Suven Life Sciences Limited (IN) | 2024-11-20 | — | — | EP | disclosed |
| EP-1984362-B1 | PROCESS FOR PREPARING INTERMEDIATES TO 5-HT4 RECEPTOR AGONIST COMPOUNDS | THERAVANCE INC (US) | 2011-05-11 | — | — | EP | disclosed |
| EP-1984362-B1 | PROCESS FOR PREPARING INTERMEDIATES TO 5-HT4 RECEPTOR AGONIST COMPOUNDS | THERAVANCE INC (US) | 2011-05-11 | — | — | EP | disclosed |
| US-7671198-B2 | Process for preparing intermediates to 5-HT4 receptor agonist compounds | THERAVANCE, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-7671198-B2 | Process for preparing intermediates to 5-HT4 receptor agonist compounds | THERAVANCE, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-7671198-B2 | Process for preparing intermediates to 5-HT4 receptor agonist compounds | THERAVANCE, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| WO-2007097976-A1 | PROCESS FOR PREPARING INTERMEDIATES TO 5-HT4 RECEPTOR AGONIST COMPOUNDS | THERAVANCE, INC. (US) | 2007-08-30 | — | — | WO | disclosed |
| US-20070191355-A1 | Process for preparing intermediates to 5-HT4 receptor agonist compounds | THERAVANCE, INC. | 2007-08-16 | — | — | US | disclosed |
| US-20070191355-A1 | Process for preparing intermediates to 5-HT4 receptor agonist compounds | THERAVANCE, INC. | 2007-08-16 | — | — | US | disclosed |
| US-20070191355-A1 | Process for preparing intermediates to 5-HT4 receptor agonist compounds | THERAVANCE, INC. | 2007-08-16 | — | — | US | disclosed |
| US-20060183901-A1 | Crystalline form of an indazole-carboxamide compound | THERAVANCE, INC. | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191355-A1 | Process for preparing intermediates to 5-HT4 receptor agonist compounds | HTR4, HTR3B, HTR5A | HTR4 1/4885SIGMAR1 204/4885PIK3CD 675/4885 |
| US-12275746-B2 | Pyrrolo[1,2-b]-2-pyridazinone compounds as 5-HT4 receptor agonists | HTR4, HTR5A, HTR1B | HTR4 1/4885SIGMAR1 267/4885PIK3CD 934/4885 |
| US-20250019386-A1 | PYRROLO[1,2-b]-2-PYRIDAZINONE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR5A, HTR1B | HTR4 1/4885SIGMAR1 267/4885PIK3CD 934/4885 |
| US-20060183901-A1 | Crystalline form of an indazole-carboxamide compound | HTR4, HTR3C, HTR5A | HTR4 1/4885SIGMAR1 41/4885PIK3CD 2115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.